{
    "clinical_study": {
        "@rank": "3013", 
        "brief_summary": {
            "textblock": "We have added objectives 4-6 to our updated study:\n\n      Study Objective 1:  To determine whether the distribution of MelaFind scores is different\n      for different patients with multiple nevi, and whether such distributions can be utilized to\n      identify \"signature\" lesions for a given patient.\n\n      Study Objective 2:  To investigate whether distributions of quantitative ABCD parameters\n      differ among patients and whether these qABCD parameters identify \"signature\" lesions.\n\n      Study Objective 3:  To determine the feasibility of defining and using relative thresholds\n      to improve the specificity of MelaFind without sacrificing its high sensitivity.\n\n      Study Objective 4: To determine the repeatability of MelaFind scores for a given lesion for\n      different patient and lesion characteristics.\n\n      Study Objective 5: To identify patient and lesion characteristics that result in the highest\n      variability of MelaFind scores for a given lesion.\n\n      Study Objective 6: To use standard errors of MelaFind scores to propose a robust individual\n      threshold for lesions to be considered for biopsy to rule out melanoma on patients with\n      multiple nevi."
        }, 
        "brief_title": "MelaFind Evaluations for Patients With Multiple Nevi", 
        "condition": "Clinically Atypical Pigmented Skin Lesion", 
        "condition_browse": {
            "mesh_term": "Pigmentation Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Cutaneous lesions examined with MelaFind must satisfy all of the following inclusion\n        criteria:\n\n        Inclusion Criteria:\n\n          -  The lesion is pigmented (i.e., melanin, keratin, blood)\n\n          -  The diameter of the pigmented area is not < 2 mm, and not > 22 mm\n\n          -  The lesion is accessible to the MelaFind\n\n          -  The patient, or a legally authorized representative, has consented to participate in\n             the study and has signed the Informed Consent Form;\n\n        Cutaneous lesions that meet any of the following exclusion criteria will not be accepted:\n\n        Exclusion Criteria:\n\n          -  The patient has a known allergy to isopropyl alcohol\n\n          -  The lesion has been previously biopsied, excised, or traumatized\n\n          -  The skin is not intact (e.g., open sores, ulcers, bleeding)\n\n          -  The lesion is within 1 cm of the eye\n\n          -  The lesion is on mucosal surfaces (e.g., lips, genitals)\n\n          -  The lesion is on palmar hands\n\n          -  The lesion is on plantar feet\n\n          -  The lesion is on or under nails\n\n          -  The lesion is located on or in an area of visible scarring\n\n          -  The lesion contains foreign matter (e.g., tattoo, splinter, marker)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who have at least one lesion that meets the inclusion/exclusion criteria (see\n        eligibility criteria below) AND each lesion enrolled must be clinically atypical (i.e.,\n        contain at least one of the following ABCDEPRU characteristics: Asymmetry, Border\n        irregularity, Color variegation, Diameter < 6 mm, Evolving, Patient's concern, Regression,\n        Ugly duckling).\n\n        Lesions should be selected to have characteristics that may affect the repeatability of\n        lesion scores:  anatomic site (often exposed to UV - sun or tanning beds - or not;\n        sun-damage may affect the repeatability); lesion diameter (6 mm, e.g. ~5 mm or > 6 mm,\n        e.g., 10 mm); and melanin content relative to normal skin (dark pigmentation or light\n        pigmentation).\n\n        A maximum of 8 lesions may be enrolled per patient"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700101", 
            "org_study_id": "20123"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 5, 2013", 
        "number_of_groups": "1", 
        "official_title": "MelaFind Evaluations for Patients With Multiple Nevi", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Multiple values and standard deviations of MelaFind scores for pigmented skin lesions", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700101"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "MELA Sciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MELA Sciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}